Approaching ASCO 2022: Reaching New Plateaus in the Treatment of Melanoma

Jeffrey S. Weber, MD, PhD


May 26, 2022

Jeffrey S. Weber, MD, PhD, looks ahead to the upcoming ASCO conference, in which he anticipates a convergence of updates on previously published studies — studies that collectively produced a necessary "plateau" or consolidation of data and generated successive investigations that have, in turn, produced new elevations.

Whether the topic is advances on neoadjuvant regimens, the latest data on survival outcomes in the RELATIVITY-047 study, the viability of treating kidney transplant patients with blockade inhibitors, or the possibilities surrounding combinations with a PD-L1 blockade, the gathering of new information guarantees a good sample of positive progress in the field of melanoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.